Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13121344 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL10216215 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL12968064 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL8280232 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL19841410 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL24328537 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL18126800 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL7883205 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL18823800 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL14400790 | 1.00 | THRB (0.38) | THRBLMNACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198339-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | US | disclosed |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3156410-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198339-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | GPR119, INSR, IGF1R | THRB 1643/4885LMNA 2410/4885CHRM2 1064/4885 |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, IAPP, INSR | THRB 258/4885LMNA 4430/4885CHRM2 866/4885 |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | GPR119, IAPP, INSR | THRB 258/4885LMNA 4430/4885CHRM2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.